Leyden Labs
Summary active Updated Jun 28, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
About
Leyden Labs is a Dutch biotech developing intranasal antibody sprays designed to block respiratory viruses at the point of entry, leveraging its Mucosal Protection Platform to protect against influenza, coronaviruses, and other respiratory viruses 12. The company’s lead program is PanFlu, based on CR9114, a broadly neutralising anti-influenza antibody targeting a conserved region of the influenza haemagglutinin 2. Leyden Labs was selected for the European Innovation Council’s STEP Scale Up programme 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-25 | Growth | €40M | European Innovation Council Fund, Invest-NL, Gates Foundation Strategic Investment Fund | ClavystBio 123 |
| 2025-10 | Growth | €30M | European Innovation Council Fund, Invest-NL | – 2 |
| 2024-01 | Series B | $70M | – | – 2 |
Invest-NL contributed €10 million of the June 2026 round 1. The round was structured as a strategic growth financing and was not labeled as a traditional venture round 2.
What Investors Say
“This investment was made because we believe Leyden Labs’ novel approach has the potential to make a meaningful impact.”
— Hermann Hauser, EIC Fund Board Member 3
“To turn breakthrough innovations into solutions that benefit society, companies need access to patient capital.”
— Ineke Cazander, Invest-NL 3
What Founders Say
“This financing represents much more than capital. It signals confidence in our scientific approach, our team, and our mission.”
Sources
-
BeBeez International, “Leyden Labs secures €40 million to develop intranasal protection against influenza and coronaviruses,” June 25, 2026. Accessed June 2026. https://bebeez.eu/2026/06/25/leyden-labs-secures-e40-million-to-develop-intranasal-protection-against-influenza-and-coronaviruses/↩↩↩↩↩
-
European Biotechnology Magazine, “Leyden Labs adds €40m for intranasal flu prevention,” June 2026. Accessed June 2026. https://european-biotechnology.com/latest-news/leyden-labs-adds-e40m-for-intranasal-flu-prevention/↩↩↩↩↩↩
-
Pulse 2.0, “Leyden Labs Raises €40 Million To Advance Respiratory Virus Protection Platform,” June 2026. Accessed June 2026. https://pulse2.com/leyden-labs-raises-e40-million-to-advance-respiratory-virus-protection-platform/amp/↩↩↩↩